dalteparin has been researched along with ximelagatran in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 23 (88.46) | 29.6817 |
| 2010's | 3 (11.54) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berkowitz, SD; Colwell, CW; Francis, CW; Ginsberg, JS; Heit, JA; Peters, G; Whipple, J | 1 |
| Arfwidsson, AC; Bylock, A; Eriksson, BI; Eriksson, UG; Fager, G; Frison, L; Gustafsson, D; Kälebo, P | 1 |
| Eriksson, UG; Fager, G; Frison, L; Gustafsson, D; Mattsson, C; Sarich, TC; Wolzt, M | 1 |
| Andersson, C; Bylock, A; Eriksson, BI; Frison, L; Gustafsson, D; Larson, G; Lindahl, TL; Wåhlander, K | 1 |
| Carlsson, S; Elg, M; Mattsson, C | 1 |
| Bergqvist, D; Bylock, A; Dahl, OE; Eriksson, BI; Eriksson, UG; Frison, L; Gustafsson, D; Kälebo, P; Lindbratt, S; Welin, L | 1 |
| Agnelli, G; Cohen, AT; Dahl, OE; Eriksson, BI; Eskilson, C; Frison, L; Mouret, P; Nylander, I; Ogren, M; Rosencher, N | 1 |
| Andersson, M; Elg, S; Eriksson, UG; Fager, G; Gustafsson, D; Mattsson, C; Sarich, TC; Schmidt, A; Wollbratt, M; Wolzt, M | 1 |
| Boström, SL; Hansson, GF; Kjaer, M; Sarich, TC | 1 |
| Eriksson, H; Frison, L; Gustafsson, D; Schulman, S; Wåhlander, K; Welin, LT | 1 |
| Berkowitz, SD; Colwell, CW; Davidson, BL; Francis, CW; Ginsberg, JS; Lieberman, JR; Lotke, PA; McElhattan, JL; Neubauer, J; Peters, GR | 1 |
| Agnelli, G; Andersson, M; Cohen, AT; Dahl, OE; Eriksson, BI; Eskilson, C; Freij, A; Kälebo, P; Lassen, MR; Mouret, P; Panfilov, S; Rosencher, N | 1 |
| Evans, HC; Faulds, D; Perry, CM | 1 |
| Boström, SL; Hansson, GF; Sarich, TC; Wolzt, M | 1 |
| Agnelli, G; Andersson, M; Cohen, A; Dahl, O; Eriksson, BI; Mouret, P; Panfilov, S; Rosencher, N | 1 |
| Pokrovskaia, EV | 1 |
| Cimminiello, C; Planès, A; Samama, MM | 1 |
| Egorova, TD; Fedorova, AIu; Kolosova, KIu; Nesterova, SG; Ol'binskaia, LI | 1 |
| Harenberg, J; Jörg, I; Weiss, C | 1 |
| Ma, Q | 1 |
| Agnelli, G; Andersson, M; Bylock, A; Cohen, AT; Dahl, OE; Eriksson, BI; Mouret, P; Ogren, M; Panfilov, S; Rosencher, N | 1 |
| Agnelli, G; Andersson, M; Bergqvist, D; Boberg, B; Bylock, A; Cohen, AT; Dahl, OE; Eriksson, BI; Jensen, E; Lassen, MR; Mouret, P; Rosencher, N | 1 |
| Depasse, F; Heptinstall, S; Kunitada, S; Oursin, A; Samama, MM | 1 |
| Burghaus, R; Coboeken, K; Gaub, T; Kuepfer, L; Lippert, J; Mueck, W; Sensse, A; Siegmund, HU; Weiss, W | 1 |
| Chu, XC; Gao, JH; Ning, B; Wang, LL; Zhao, CX | 1 |
3 review(s) available for dalteparin and ximelagatran
| Article | Year |
|---|---|
Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery.
Topics: Anticoagulants; Azetidines; Benzylamines; Drug Interactions; Drug Therapy, Combination; Enoxaparin; Glycine; Humans; Orthopedic Procedures; Randomized Controlled Trials as Topic; Thrombin; Thromboembolism; Venous Thrombosis; Warfarin | 2004 |
[Novel possibilities of antithrombotic therapy in patients with chronic heart failure].
Topics: Anticoagulants; Azetidines; Benzylamines; Dalteparin; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Fondaparinux; Heart Failure; Humans; Multicenter Studies as Topic; Oligosaccharides; Placebos; Polysaccharides; Randomized Controlled Trials as Topic; Risk Factors; Thromboembolism; Thrombomodulin; Thrombosis; Time Factors; Venous Thrombosis | 2005 |
Effects of different anticoagulant drugs on the prevention of complications in patients after arthroplasty: A network meta-analysis.
Topics: Anticoagulants; Arthroplasty; Azetidines; Benzylamines; Dabigatran; Enoxaparin; Heparin; Heparin, Low-Molecular-Weight; Humans; Network Meta-Analysis; Postoperative Complications; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Treatment Outcome; Venous Thromboembolism; Warfarin | 2017 |
17 trial(s) available for dalteparin and ximelagatran
| Article | Year |
|---|---|
Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Azetidines; Benzylamines; Dose-Response Relationship, Drug; Drug Administration Schedule; Enoxaparin; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Postoperative Complications; Prodrugs; Pulmonary Embolism; Thrombin; Treatment Outcome; Venous Thrombosis | 2001 |
A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in
Topics: Administration, Oral; Adolescent; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzylamines; Dalteparin; Female; Glycine; Humans; Incidence; Injections, Subcutaneous; Male; Middle Aged; Partial Thromboplastin Time; Postoperative Complications; Prodrugs; Safety; Sweden; Thrombin; Thromboembolism; Treatment Outcome; Venous Thrombosis | 2002 |
Inhibition of thrombin generation by the oral direct thrombin inhibitor ximelagatran in shed blood from healthy male subjects.
Topics: Administration, Oral; Adult; Anticoagulants; Antithrombin III; Azetidines; Benzylamines; Dalteparin; Feedback; Humans; Male; Peptide Fragments; Peptide Hydrolases; Prothrombin; Thrombin | 2002 |
Factor V Leiden (G1691A) and prothrombin gene G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery.
Topics: Activated Protein C Resistance; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzylamines; Dalteparin; DNA Mutational Analysis; Double-Blind Method; Europe; Factor V; Female; Genetic Predisposition to Disease; Genotype; Glycine; Humans; Male; Middle Aged; Postoperative Complications; Promoter Regions, Genetic; Prospective Studies; Prothrombin; Pulmonary Embolism; Risk Factors; Thrombophilia; Venous Thrombosis | 2002 |
Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial.
Topics: Adult; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzylamines; Dalteparin; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Glycine; Humans; Male; Middle Aged; Postoperative Complications; Prodrugs; Thromboembolism | 2002 |
Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzylamines; Cause of Death; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Glycine; Hemorrhage; Humans; Injections, Subcutaneous; Male; Middle Aged; Postoperative Complications; Prodrugs; Prospective Studies; Pulmonary Embolism; Safety; Thrombin; Treatment Outcome; Venous Thrombosis | 2003 |
Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects.
Topics: Administration, Oral; Adult; Azetidines; Benzylamines; Dose-Response Relationship, Drug; Enoxaparin; Fibrinolytic Agents; Hirudins; Humans; Male; Platelet Activation; Recombinant Proteins; Reference Values; Thrombin | 2003 |
Effects of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, and dalteparin on the endogenous thrombin potential in venous blood from healthy male subjects.
Topics: Administration, Oral; Adult; Anticoagulants; Azetidines; Benzylamines; Dalteparin; Factor Xa Inhibitors; Glycine; Humans; Inhibitory Concentration 50; Injections, Subcutaneous; Male; Reference Values; Thrombin; Time Factors; Veins | 2003 |
A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Azetidines; Benzylamines; Dalteparin; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Leg; Male; Middle Aged; Phlebography; Prodrugs; Radionuclide Imaging; Treatment Outcome; Venous Thrombosis; Warfarin | 2003 |
Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study.
Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Azetidines; Benzylamines; Double-Blind Method; Enoxaparin; Female; Hemorrhage; Hemostatics; Humans; Male; Middle Aged; Prodrugs; Random Allocation; Thrombin; Thromboembolism; Venous Thrombosis; Wound Healing | 2003 |
The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzylamines; Double-Blind Method; Enoxaparin; Female; Glycine; Hemorrhage; Humans; Male; Middle Aged; Preoperative Care; Therapeutic Equivalency; Thrombin; Thromboembolism; Venous Thrombosis | 2003 |
The inhibitory effect of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, compared with enoxaparin and r-hirudin on ex vivo thrombin generation in human plasma.
Topics: Administration, Oral; Adult; Anticoagulants; Area Under Curve; Azetidines; Benzylamines; Blood Coagulation Tests; Dose-Response Relationship, Drug; Enoxaparin; Hirudins; Humans; Infusions, Intravenous; Injections, Subcutaneous; Male; Prodrugs; Safety; Thrombin; Time Factors | 2004 |
Significantly lower need for blood transfusions associated with post-operatively initiated subcutaneous melagatran/oral ximelagatran compared with enoxaparin.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzylamines; Blood Transfusion; Drug Therapy, Combination; Enoxaparin; Glycine; Humans; Logistic Models; Odds Ratio; Time Factors | 2004 |
Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran.
Topics: Administration, Oral; Anticoagulants; Arteries; Azetidines; Benzylamines; Drug Therapy, Combination; Enoxaparin; Follow-Up Studies; Germany; Hemorrhage; Humans; Incidence; International Normalized Ratio; Muscle, Skeletal; Prospective Studies; Recurrence; Retinal Vein Occlusion; Time Factors; Venous Thrombosis; Warfarin | 2006 |
Assessment of bleeding after concomitant administration of antiplatelet and anticoagulant agents in lower limb arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arthroplasty; Aspirin; Azetidines; Benzylamines; Bleeding Time; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Enoxaparin; Europe; Female; Humans; Lower Extremity; Male; Middle Aged; Platelet Aggregation Inhibitors; South Africa; Thrombosis | 2006 |
Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Anticoagulants; Arthroplasty, Replacement, Hip; Azetidines; Benzylamines; Double-Blind Method; Enoxaparin; Female; Hip Fractures; Humans; Liver; Male; Middle Aged; Postoperative Complications; Time Factors; Venous Thromboembolism | 2009 |
Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: a randomised controlled trial in healthy elderly adults.
Topics: Administration, Cutaneous; Administration, Oral; Aged; Anticoagulants; Antithrombins; Azetidines; Benzylamines; Blood Coagulation; Dalteparin; Factor Xa Inhibitors; Female; Humans; Male; Pyridines; Thiazoles; Thrombosis | 2010 |
6 other study(ies) available for dalteparin and ximelagatran
| Article | Year |
|---|---|
Effects of ximelagatran, the oral form of melagatran, in the treatment of caval vein thrombosis in conscious rats.
Topics: Administration, Oral; Animals; Anticoagulants; Azetidines; Benzylamines; Dalteparin; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Glycine; Hirudins; Male; Prodrugs; Rats; Rats, Sprague-Dawley; Thrombosis; Venae Cavae | 2002 |
[The first oral thrombin inhibitor. Competition to heparins and marcumar?].
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzylamines; Clinical Trials as Topic; Enoxaparin; Fibrinolytic Agents; Glycine; Humans; Phenprocoumon; Placebos; Prodrugs; Thrombin; Thromboembolism; Thrombosis; Time Factors | 2003 |
[Novel antithrombotic drugs. From the 19th Congress of the International Society on Thrombosis and Haemostasis].
Topics: Adult; Age Factors; Aged; Anticoagulants; Azetidines; Benzylamines; Dalteparin; Female; Fibrinolytic Agents; Fondaparinux; Humans; Male; Middle Aged; Multicenter Studies as Topic; Oligosaccharides; Placebos; Polysaccharides; Prodrugs; Pulmonary Embolism; Randomized Controlled Trials as Topic; Thromboembolism; Thrombomodulin; Time Factors; Warfarin | 2004 |
Prevention of venous thromboembolism after orthopedic surgery: the EXPRESS study.
Topics: Anticoagulants; Azetidines; Benzylamines; Clinical Trials as Topic; Dissent and Disputes; Enoxaparin; Glycine; Humans; Orthopedic Procedures; Therapeutic Equivalency; Thromboembolism; Treatment Outcome; Venous Thrombosis | 2004 |
Development of oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dabigatran; Drug Delivery Systems; Drug Design; Enoxaparin; Factor Xa Inhibitors; Humans; Morpholines; Postoperative Hemorrhage; Pyridines; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis; Warfarin | 2007 |
Evaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulation.
Topics: Anticoagulants; Azetidines; Benzylamines; Blood Circulation; Blood Coagulation; Computer Simulation; Enoxaparin; Humans; Models, Biological; Morpholines; Naphthalenes; Partial Thromboplastin Time; Propionates; Rivaroxaban; Thiophenes; Translational Research, Biomedical; Treatment Outcome; Warfarin | 2011 |